Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
PubMed for Bookshelf ID: 4862464
3 results
Filters applied: . Clear all
Page 1
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
J Bone Miner Res. 2018 Aug;33(8):1383-1393. doi: 10.1002/jbmr.3475. Epub 2018 Jun 26.
J Bone Miner Res. 2018.
PMID: 29947083
Free article.
Clinical Trial.
Burosumab: First Global Approval.
Lamb YN.
Lamb YN.
Drugs. 2018 Apr;78(6):707-714. doi: 10.1007/s40265-018-0905-7.
Drugs. 2018.
PMID: 29679282
Review.
Item in Clipboard
X-Linked Hypophosphatemia and FGF23-Related Hypophosphatemic Diseases: Prospect for New Treatment.
Kinoshita Y, Fukumoto S.
Kinoshita Y, et al.
Endocr Rev. 2018 Jun 1;39(3):274-291. doi: 10.1210/er.2017-00220.
Endocr Rev. 2018.
PMID: 29381780
Review.
Item in Clipboard
Cite
Cite